Filter by: patients
What is Carbidopa-Levodopa CR?

A controlled release preparation of carbidopa/levodopa formulated to release a lower, smoother dose of medication. It is sometimes taken last thing at night in order to maintain dopamine levels throughout sleep and into the morning.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Parkinson's Disease 246 50 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Stiffness/Spasticity 23 5 Efficacy_major Efficacy_moderate
Other 15 5 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none
Improve mobility 7 2 Efficacy_moderate Efficacy_cant_tell
Sleep problems 6 2 Efficacy_major Efficacy_slight
Slowness 5 1 Efficacy_major

See all 357 patients currently taking Carbidopa-Levodopa CR

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
4
Moderate
18
Mild
17
None
35

Reported Dosages

Frequently reported dosages based on patients currently taking Carbidopa-Levodopa CR. See all 72 dosages

  daily 25 mg-100 mg daily 50 mg-200 mg daily 2 x 25 mg-100 mg daily 3 x 25 mg-100 mg daily 2 x 50 mg-200 mg daily 4 x 25 mg-100 mg daily 3 x 50 mg-200 mg daily 4 x 50 mg-200 mg daily 5 x 50 mg-200 mg daily
  11 Number of Patients: 11 58 Number of Patients: 58 43 Number of Patients: 43 18 Number of Patients: 18 22 Number of Patients: 22 14 Number of Patients: 14 22 Number of Patients: 22 20 Number of Patients: 20 14 Number of Patients: 14 11 Number of Patients: 11  

Reported Stop Reasons

Why Patients Stopped Taking Carbidopa-Levodopa CR (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 28   Doctor's advice: 46%
Did not seem to work 13   Did not seem to work: 21%
Other 12   Other: 20%
Side effects too severe 10   Side effects too severe: 16%
Personal research 5   Personal research: 8%
Expense 1   Expense: 2%
Course of treatment ended 1   Course of treatment ended: 2%
Change in health plan coverage 1   Change in health plan coverage: 2%
Not indicated 1   Not indicated: 2%

See all 60 patients who’ve stopped taking Carbidopa-Levodopa CR

Currently Taking Carbidopa-Levodopa CR

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Carbidopa-Levodopa CR

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Carbidopa-Levodopa CR

Always
55 74%
Usually
17 23%
Sometimes
1 1%
Never
1 1%

Burden

Difficulty being on treatment

Burden of Carbidopa-Levodopa CR

Very
5 7%
Somewhat
6 8%
A little
16 22%
Not at all
47 64%

Cost

Paid out of pocket

Cost of Carbidopa-Levodopa CR

$200+
2 4%
$100-199
2 4%
$50-99
6 12%
$25-49
4 8%
< $25
38 73%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 12, 2012.